Get the Stockscreener App
1.937
0.00%
0.097
Quince Therapeutics Inc stock is traded at $1.937, with a volume of 41,988.
It is up +0.00% in the last 24 hours and up +125.35% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
See More
Previous Close:
$1.84
Open:
$1.85
24h Volume:
41,988
Relative Volume:
0.08
Market Cap:
$79.62M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-2.3337
EPS:
-0.83
Net Cash Flow:
$-18.45M
1W Performance:
-3.16%
1M Performance:
+125.35%
6M Performance:
+113.95%
1Y Performance:
+111.28%
1-Day Range:
$1.80
$1.92
1-Week Range:
$1.621
$2.1356
52-Week Range:
$0.5116
$2.1356
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| QNCX | 1.92 | 79.62M | 0 | -31.39M | -18.45M | -0.83 |
| VRTX | 447.05 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.92 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Quince Therapeutics Inc Stock (QNCX) Latest News
Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat
QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia
Quince Therapeutics Advances Phase 3 Trial with $47.8M Cash Runway Through 2026 | QNCX Stock News - StockTitan
Quince Therapeutics' EryDex Shows Promise in Phase 3 Ataxia Trial, Key Data Revealed | QNCX Stock News - StockTitan
Quince Therapeutics reports positive safety data for EryDex - Investing.com India
Quince Therapeutics reports positive safety data for EryDex By Investing.com - Investing.com UK
Quince Therapeutics' EryDex Shows Promising Safety Data in Phase 3 A-T Trial | QNCX Stock News - StockTitan
Quince Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group - MarketBeat
Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
QNCX stock touches 52-week high at $1.44 amid market optimism - Investing.com UK
Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com
Rodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
US Penny Stocks To Watch In October 2024 - Yahoo Finance
Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada
Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World
Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World
Quince Therapeutics CEO acquires $107k in company stock - Investing.com
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily
Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News
Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News
Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena
Phase III data on Quince Therapeutics’ EryDex - The Pharma Letter
Quince Therapeutics reports progress in A-T treatment study - Investing.com
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - StockTitan
Quince Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Market Resilience: Quince Therapeutics Inc (QNCX) Finishes Weak at 0.58, Down -16.54 - The Dwinnex
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan
Quince Therapeutics (NASDAQ:QNCX) Trading Up 2.6% - Defense World
Reviewing Genenta Science (NASDAQ:GNTA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial - Clinical Trials Arena
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia ... - Business Wire
Quince Therapeutics (NASDAQ:QNCX) versus Kymera Therapeutics (NASDAQ:KYMR) Critical Review - Defense World
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Business Wire
Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Quince Therapeutics faces Nasdaq delisting over share price - Investing.com
Stock Surge: Quince Therapeutics Inc (QNCX) Closes at 0.68, Marking a -4.23 Increase/Decrease – DWinneX - The Dwinnex
Critical Review: Autolus Therapeutics (NASDAQ:AUTL) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - br.ADVFN.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Jun 04 '24 |
Option Exercise |
0.55 |
56,061 |
30,834 |
257,616 |
| Thye Dirk | CHIEF EXECUTIVE OFFICER |
Jan 16 '24 |
Option Exercise |
0.79 |
240,530 |
190,791 |
689,441 |
| Lamond David | Director |
Dec 14 '23 |
Buy |
1.04 |
22,627 |
23,532 |
2,347,545 |
| Lamond David | Director |
Dec 12 '23 |
Buy |
1.02 |
22,327 |
22,774 |
2,302,291 |
| Lamond David | Director |
Dec 13 '23 |
Buy |
1.00 |
22,627 |
22,627 |
2,324,918 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):